247
Participants
Start Date
July 29, 2020
Primary Completion Date
March 31, 2025
Study Completion Date
March 31, 2025
DKN-01 300mg
Administered by IV infusion
DKN-01 600mg
Administered by IV infusion
DKN-01 400mg
Administered by IV infusion
Tislelizumab 200mg
Administered by IV infusion
Tislelizumab 400mg
Administered by IV infusion
Oxaliplatin
Administered by IV infusion
Capecitabine 1000mg/ m2 twice daily (BID)
Administered orally
Leucovorin Calcium
Administered by IV infusion
Fluorouracil
Administered by IV infusion
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea St. Mary's Hospital, Seoul
Columbia University Irving Medical Center, New York
National Cancer Center, Goyang
Charité Universitätsmedizin Berlin, Berlin
CHA Bundang Medical Center, Seongnam-si
Seoul National University Bundang Hospital, Seongnam
Hallym University Sacred Heart Hospital, Anyang
Korea University Ansan Hospital, Ansan-si
The Catholic University of Korea St. Vincent's Hospital, Suwon
Fox Chase Cancer Center, Philadelphia
Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg
Gachon University Gil Medical Center, Incheon
Inha University Hospital, Incheon
Duke University Medical Center, Durham
Mayo Clinic Florida, Jacksonville
AdventHealth Cancer Institute, Orlando
Dong-A University Hospital, Busan
University of Wisconsin Carbone Cancer Center, Madison
Institut Fur Klinisch Onkologische Forschung Am Krankenhaus Nordwest, Frankfurt
Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago
University of Chicago, Chicago
Caritas Klinikum Saarbrücken St. Theresia, Saarbrücken
Universitatsklinikum Heidelberg, Heidelberg
Pontchartrain Cancer Center, Covington
Slk-Kliniken, Heilbronn
MD Anderson Cancer Center, Houston
Mayo Clinic Cancer Center, Phoenix
University of Arizona, Tucson
Studienzentrum Onkologie Ravensburg, Ravensburg
The Angeles Clinic Research Institute - A Cedars-Sinai Affiliate, Los Angeles
University of Southern California, Los Angeles
UCLA, Los Angeles
City of Hope, Duarte
Hoag Memorial Hospital Presbyterian, Newport Beach
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
University of California San Francisco, San Francisco
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Rhode Island Hospital, Providence
Korea University Anam Hospital, Seoul
Hanyang University Hospital, Seoul
Asan Medical Center, Seoul
Boramae Hospital SNU, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
Collaborators (1)
BeiGene
INDUSTRY
Leap Therapeutics, Inc.
INDUSTRY